Tag: MDMA assisted psychotherapy

  • When Culture Moves Faster Than Science: Psilocybin Is Already in Your Clinic

    When Culture Moves Faster Than Science: Psilocybin Is Already in Your Clinic

    Here is what happens when culture moves faster than science.

    Before psilocybin becomes an FDA-approved treatment, before every safety question is answered, before we know how to responsibly scale psychedelic-assisted therapy, millions of Americans are already using it.

    According to a newly published analysis of the 2024 National Survey on Drug Use and Health, approximately 2.8% of Americans age 12 and older reported using psilocybin in the past year, corresponding to roughly 8 million people nationally. The study analyzed survey data from 58,633 respondents, and 2024 was the first year NSDUH included psilocybin-specific questions. 

    This is important, not because every person using psilocybin is doing something dangerous. Not because psilocybin has no therapeutic potential. The emerging research signal in depression, treatment-resistant depression, and substance use disorders is real enough to deserve rigorous study. In fact, the FDA recently announced regulatory actions intended to accelerate development of psychedelic-related treatments, including psilocybin for treatment-resistant depression and major depressive disorder. 

    But the problem is this: public enthusiasm is not the same thing as clinical evidence.

    And right now, the public is not waiting for the randomized controlled trials to finish.

    The survey found that psilocybin use was more common among males, young adults ages 18 to 25, and college-educated individuals. It was also strongly associated with use of cannabis, LSD, ketamine, and MDMA. 

    Most importantly for psychiatrists, psilocybin use was not randomly distributed across the population. People with a past-year major depressive episode were more likely to report psilocybin use. So were individuals with alcohol use disorder. 

    Because this means the people most likely to be experimenting with psilocybin are not necessarily the healthy, psychologically stable adults often imagined in wellness culture. They may be the very patients already sitting in our offices: depressed, anxious, drinking heavily, using cannabis, struggling with treatment resistance, frustrated with conventional psychiatry, or searching for something that feels more meaningful than another medication adjustment.

    This is where psychiatry has to grow up.

    The easy response is dismissal. “It’s illegal.” “It’s recreational.” “It’s just another drug trend.” That response will fail because it ignores what patients are already doing.

    The equally dangerous response is romanticization. “It’s natural.” “It’s ancient.” “It expands consciousness.” “It heals trauma.” That response also fails because it replaces medical evidence with cultural mythology.

    The clinical response has to be more serious than both.

    Psilocybin used in a controlled clinical trial is not the same thing as psilocybin used at home, at a retreat, at a party, in combination with cannabis, alcohol, MDMA, ketamine, or while taking serotonergic medications. Clinical trials involve screening, standardized dosing, structured preparation, psychological support, monitoring, and follow-up. Naturalistic use often has none of those safeguards.

    A patient with depression using psilocybin outside a clinical setting may be doing so because they are desperate, not because they are reckless. But desperation does not eliminate risk. Psychedelic experiences can be psychologically destabilizing. They can worsen anxiety, trigger panic, create prolonged distress, or complicate underlying bipolar spectrum illness, psychosis vulnerability, trauma symptoms, or substance use disorders.

    This does not mean psychiatrists should lecture patients.

    It means we should ask better questions.

    Not: “Are you using drugs?”

    But:
    “Have you used psilocybin, mushrooms, ketamine, MDMA, LSD, or other psychedelic substances in the past year?”
    “What were you hoping it would help with?”
    “What happened during and after the experience?”
    “Did you use it alone or with others?”
    “Were alcohol, cannabis, or other substances involved?”
    “Did it change your mood, sleep, anxiety, impulsivity, suicidal thoughts, or sense of reality afterward?”
    “Are you planning to use it again?”

    That is not endorsement. That is clinical reality.

    Whether psilocybin eventually becomes an FDA-approved psychiatric treatment or not, psychiatrists are going to see more patients who have used it, are considering using it, or believe it has already treated their depression, trauma, addiction, or existential distress.

    We need to be ready for that conversation.

    The future of psychedelic medicine should not be driven by excessive enthusiasm, venture capital, wellness influencers, or reactionary fear. It should be driven by careful science, honest risk assessment, clinical humility, and respect for the fact that patients are already making decisions before the field has reached consensus.

    Culture has moved first.

    Science is catching up.

    Psychiatry needs to be in the room before the narrative is written without us.

    Psychiatry Unfiltered

  • Psychedelics Open the Door Then What?

    Psychedelics Open the Door Then What?

    Someone left a comment on my YouTube channel a while back: “He doesn’t know anything, he’s just a new graduate.” Fair enough. I should probably update my profile.

    For the record, I’ve been practicing psychiatry for five years post-residency now, and to put it mildly, I’ve seen a few things. I’ve sat across from patients fighting depression that won’t lift, PTSD that won’t quiet, bipolar illness that won’t stabilize, and the often-forgotten but equally devastating problem of simply trying to live a daily life. In the most complex cases, I struggle right alongside them. It takes a real toll on both sides of the therapeutic relationship. I didn’t enter medicine, and certainly not psychiatry, to helplessly watch people suffer.

    How I Got Hooked (No Pun Intended)

    I remember attending my first American Academy of Addiction Psychiatry annual meeting with my best friend, two excited second-year residents with a budding interest in addiction medicine. There were dozens of strong lectures that week, but one track lit me up: a series on psychedelic research, including data on mystical experience and the use of psilocybin in patients with terminal cancer.

    I was hooked. The work was compelling, novel, and almost completely absent from the standard residency curriculum. The literature has only grown since, building on a body of clinical research and on centuries of indigenous and traditional experience that came long before any of us showed up to a conference.

    Why the Psychedelic Conversation Matters Now

    People have told me my entire field is “pseudoscience at best.” I prefer to think of psychiatry as the most interpretive part of medicine, but everyone is entitled to an opinion.

    What most people across the spectrum do agree on is this: collective mental health is getting worse, and the current standard of care leaves a lot of people out in the cold. There is a large gap, and it is begging to be filled. Right now, renewed clinical and cultural interest in psychedelics is rushing in to fill it.

    Everything old is new again. Postwar America saw a similar wave in the 1960s, a counterculture pushing back against the status quo with these compounds in hand, and we blew it. We were reckless, the political backlash was severe, and the scientific window slammed shut for a generation. We have a chance now to do this differently: to do the actual science, to understand these medicines, and to deliver them safely. I have written extensively about that elsewhere, and I will continue to.

    This piece is about something else.

    What I’ve Actually Seen in the Room

    After five years of treating serious mental illness, treatment-resistant depression, and addiction, here is the unglamorous clinical truth I want anyone considering psychedelic therapy to hear:

    I have rarely seen lasting recovery come from medication alone.

    Not on SSRIs. Not on mood stabilizers. Not on stimulants. And, this is the part the hype train usually skips, not on psychedelics either.

    Medication can take the edge off. It can crack a window in a sealed room. But without a concerted effort to change how a person thinks, what they believe about themselves, and how they show up in their own life, relief is often partial and temporary. Old patterns reassert themselves with depressing reliability.

    Being well, actually well, not just less symptomatic, is a far more complex process than adding a molecule. Even when that molecule is a powerful psychedelic that can temporarily reroute the circuits that have run a patient’s life into the ground.

    The Onion and the Ego

    This is where ego dissolution comes in.

    Psychedelics, used well, can do something extraordinary. They can peel back the layers, the conditioning, the wounds, the social performance, the inherited beliefs – and offer a person something close to a blank canvas. The experience is often described as a multi-stage journey: a descent into the subconscious, a confrontation with personal shadow material, and an ascent toward integration. Anyone who has sat with patients in the days after a session knows that structure is not imaginary.

    But dissolving the ego is only half the work. Maybe less.

    There has to be a rebuilding. Otherwise, the process can end in chaos, disorientation, drift, or destabilization. For all the cultural and societal programming embedded in the ego, the ego also has a job. It organizes. It protects. It gives a person a sense of continuous self. You do not want it gone so much as loosened, examined, and put back together with more skill.

    A Spiritual Problem in a Secular Age

    Here is where I will say something that may cost me a few subscribers: for many patients, psychedelic experiences can feel like a return to something sacred, however they define it.

    Nietzsche famously wrote, “God is dead. God remains dead. And we have killed him.” That line is usually quoted as a takedown of religion. I read it more as a diagnosis. Religious authority is not what it used to be, fine, but the bigger problem is the void it left behind. Not a physical void. An existential one. And that is much harder to fill.

    A great deal of suffering in modern mental health is not only symptomatic. It is existential. It is about disconnection, meaning, identity, and the felt sense that nothing larger is holding the pieces together. This is where psychedelics, used carefully, may do something SSRIs cannot. The mystical experience, that sense of being part of something larger, more connected, less small, is precisely what many patients are starving for. It offers a temporary transcendence of the cages we live inside and a reminder that the ego’s account of who we are is not the whole story.

    The Limitation Nobody Wants to Talk About

    Here is the catch, and it is a big one.

    Psychedelics can show us the possibility of what we could be and how the world could feel. They do not teach us how to embody that possibility once we come back down.

    It is like buying the book that is supposed to change your life, finishing it, and realizing it handed you the concept but not the protocol. The map, not the legs.

    In my view, this will be one of the central questions of the psychedelic revolution in both medicine and culture: when we strip away the layers that make us who we think we are, what do we replace them with?

    Will the medicine alone be enough? I do not think so. For people to genuinely transcend rigid thought patterns and live differently, something larger has to shift: a societal opening toward the slow work of integration, lived community, meaning-making, and the willingness to pursue some form of inner life without being constantly dragged back by money, politics, and a version of the American dream that has metabolized into burnout for much of the country.

    Without some broader change in how we live, think, and treat each other, psychedelic therapy risks becoming a high-end coping mechanism. People will dose, briefly touch something profound, and then return to the same conditions that drove the depression in the first place. So they will dose again. And again.

    What the Old-Timers Knew

    This is both a beacon of hope and a cautionary tale, and not from me. From the people who walked this path long before psychiatry got around to studying it. The medicines open the door. They do not walk you through it.

    The deepest insight – the one many patients eventually report after the sessions, the integration, and the work – is almost embarrassingly simple: the beauty of everyday life and ordinary connection was already there. The medicine just got the ego out of the way long enough to let them see it.

    The work, your work, my work, our work, is figuring out how to keep seeing it once the medicine wears off.

  • The psychedelic conversation in psychiatry is at an inflection point

    The psychedelic conversation in psychiatry is at an inflection point

    I believe these treatments deserve serious study. In fact, some of the most promising work in modern psychiatry is happening in this space. Psilocybin has FDA breakthrough therapy designation for treatment-resistant depression, MDMA-assisted therapy has shown meaningful promise in PTSD, and ibogaine is generating legitimate research interest in opioid use disorder and traumatic brain injury. 

    But promise is not proof.

    In my new Psychiatric Times article, I make the case that psychedelics deserve real science, not political shortcuts, podcast-driven enthusiasm, or regulatory acceleration built on weak evidence. The core issue is not whether we should study these compounds. We should. The issue is whether observational data, open-label studies, and viral claims are being asked to carry more weight than they should. 

    When a treatment has real risks, especially one like ibogaine with known cardiac concerns, the answer cannot be to lower the evidentiary bar. It has to be to raise the quality of the research. That means adequately powered randomized trials, careful safety monitoring, standardized outcomes, and enough humility to admit what we do not yet know. 

    Psychiatry does need better tools. Our patients need them badly. But if we want innovation that lasts, it has to be built on rigor, not hype.

    My latest piece in Psychiatric Times“Psychedelics Deserve Real Science”

  • The Dirty Little Secret They Won’t Tell You About Psychedelics

    The Dirty Little Secret They Won’t Tell You About Psychedelics

    It’s obvious to me, but I think the public, including many of our patients, remains unaware of a crucial truth: Psychedelics will not cure your depression, your PTSD, or your difficult life circumstances.

    There’s a growing wave of enthusiasm around psychedelics as miracle cures for mental health conditions, but the hard reality is that the evidence just doesn’t back it up—at least not yet. Even if you find yourself on the hopeful side, believing we desperately need alternatives to alleviate people’s suffering, the reported benefits of these substances have not been validated by large, rigorous, randomized controlled trials. The buzz around psychedelics often overshadows the fact that they lack the necessary scientific backing to support their mainstream use in treating complex mental health issues like depression or PTSD.

    Let’s not ignore the financial stakes here either: The people promoting these drugs stand to make billions of dollars. There’s a lot of money on the table, and many in the academic community are rallying behind these companies. But we should ask ourselves—are they doing so because of solid science or because of the potential financial windfall?

    These drugs have been around for decades, yet one consistent truth I’ve observed in every person I’ve known who’s used them is this: You must use them repeatedly, and they almost always experience a relapse of symptoms over time. There’s no permanent fix here, just a temporary reprieve, if even that.

    We can draw parallels with other treatments like ECT (electroconvulsive therapy) and ketamine. Both have shown promise in certain cases, but I’ve yet to see anyone cured by these treatments. We often perform maintenance ECT and maintenance ketamine therapy for this very reason. Just like psychedelics, they might offer temporary relief, but they don’t provide long-term solutions without ongoing interventions.

    I understand this may come off as cynical, but I’ve seen too many people fall for the hype, only to be disappointed later. People far more charismatic than me will try to convince you that psychedelics will cure everything that ails you—for a hefty price tag. Don’t buy into it without questioning the science and the motives behind the push.

  • Setback for MDMA Therapy: FDA’s Rejection and Key Concerns Explained

    Setback for MDMA Therapy: FDA’s Rejection and Key Concerns Explained

    The FDA’s decision to reject MDMA (methylenedioxymethamphetamine) for medical use typically stems from various concerns related to safety, efficacy, and potential for abuse.

    Background

    MDMA is primarily known as a recreational drug, often associated with rave and party scenes. However, it has been studied for its potential therapeutic benefits, particularly in the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions.

    Safety Concerns

    1. Neurotoxicity: Research has shown that MDMA can be neurotoxic, causing damage to serotonin-producing neurons in the brain. This can lead to long-term cognitive deficits, including memory problems and mood disorders.
    2. Cardiovascular Risks: MDMA increases heart rate and blood pressure, which can pose significant risks to individuals with underlying heart conditions. The stimulant effect can lead to hyperthermia (overheating) and dehydration.
    3. Acute Toxicity: Overdose can lead to severe hyperthermia, serotonin syndrome, and even death. The narrow therapeutic window between a therapeutic dose and a toxic dose is a significant concern.

    Efficacy Concerns

    1. Clinical Trial Results: While there have been promising results in some clinical trials, the FDA requires extensive, well-controlled studies to confirm a drug’s efficacy. If trials do not meet these rigorous standards, the FDA may not approve the drug.
    2. Long-term Benefits: The long-term efficacy of MDMA therapy is still uncertain. While short-term benefits have been observed, there is a need for more data on the sustainability of these effects.

    Potential for Abuse and Addiction

    1. Recreational Use: MDMA is widely used recreationally, which increases the potential for misuse and addiction. The FDA must consider the risk of the drug being diverted for non-medical use.
    2. Dependence: There is evidence that regular use of MDMA can lead to psychological dependence, and managing this risk is crucial in the context of medical approval.

    Regulatory and Ethical Considerations

    1. Ethical Concerns: The use of a psychoactive substance in a therapeutic setting raises ethical questions, particularly regarding informed consent and the management of potential adverse effects.
    2. Regulatory Framework: The FDA has stringent requirements for approving new medications, including ensuring that benefits outweigh risks. For a drug like MDMA, where the risks are significant, the bar for approval is high.

    Conclusion

    The FDA panel recently rejected the use of MDMA-assisted psychotherapy for treating PTSD, marking a significant setback for advocates of this treatment approach. The advisory committee, in a vote of 9-2, concluded that the current evidence does not support the effectiveness of MDMA in treating PTSD. Additionally, they voted 10-1 against the benefits of MDMA therapy outweighing its risks​. 

    Several key concerns led to this decision. Firstly, issues were raised about the integrity and validity of the clinical trials conducted by Lykos Therapeutics, including potential biases, functional unblinding, and allegations of misconduct. The panel also highlighted gaps in the data, particularly regarding the potential for abuse and adverse cardiovascular events associated with MDMA​​.

    Despite the panel’s recommendation, the FDA is not obligated to follow their advice, though it often does. The outcome has disappointed many proponents of MDMA-assisted therapy, who argue that the treatment could provide much-needed relief for PTSD patients who have not benefited from existing therapies​. 

  • Can MDMA Cure Post Traumatic Stress Disorder (PTSD).

    Can MDMA Cure Post Traumatic Stress Disorder (PTSD).

    Introduction

    The entactogen MDMA overlaps with the chemical structure of methamphetamine and mescaline and has biological effects similar to epinephrine, dopamine, and serotonin. 

    It increases the release of monoamines through the reversal of transporter proteins and reuptake inhibition specifically serotonin and norepinephrine. Not only does it block reuptake of serotonin and norepinephrine it enhances the release as well and inhibits VMAT preventing the packaging of monoamines into vesicles making more available for release. It also modulates glucocorticoids through the HPA axis, decreases amygdala and hippocampal activity, increases oxytocin, and increase prefrontal cortex activity. 

    Medical Use

    MDMA started out as a therapeutic agent to enhance blood clotting for surgical procedures and trauma. Turns out it does not work very well for that indication, who would have thought. It’s currently listed as a schedule I substance (defined as having no accepted medical use, high abuse potential, and lack of accepted safety). 

    It was later discovered to have “empathogenic effects” helping individuals who use the medication to feel more connected to their fellow human beings. After all isn’t that what we are all after? A deep connection to others and people who truly understand us. The original name for the drug was empathy, but that has changed over the years to molly and escstcy. Personally, I like names that describe what a drug does, and empathy or empath is just so much more marketable don’t you think?

    Why PTSD is a Big Problem

    With several recent wars in both Iraq and Afghanistan, America has a PTSD problem with many combat veterans returning home and requiring treatment. If you ever treated patients with PTSD than you know it’s difficult and the therapy can be intense. Many patients are unable to sit with the discomfort required to reconsolidate these memories. Having worked at the VA for one year I was surprised by the number of vets with non-combat related PTSD. Honestly, they the vast majority of my cases were people who had accidents while working or in training and subsequently developed PTSD. 

    The idea is we need methods to enhance the efficacy and speed of trauma focused psychotherapies. What better way to do that than with empathy a medication that enhances feelings of connection. The basic idea being the patient would be given MDMA and then undergo psychotherapy and by using the medication it can influence fear extinction and memory reconsolidation. There are many mechanisms at play including effects on dopamine, serotonin, BDNF, cortisol, and oxytocin. 

    The concept of using a psychedelic drug to enhance the effects of psychotherapy is not a new concept, and was done for years using LSD and other compounds. What is different now, is we are trying to put the scientific rigor behind the studies to prove that it works better than placebo, and to learn more about the mechanism of action. 

    I want to point out that the main benefit of all these psychedelic medications seems to be enhanced neuroplasticity and the ability to form new connections in critical neurocircuits much easier than would otherwise be possible. 

    Benefits of MDMA Assisted Psychotherapy

    -Increase blood flow to the vmPFC decreasing activation of the amygdala largely responsible for the fear response 

    -Enhance the production of BDNF which improves the long-term potentiation and memory consolidation 

    -Elevate the stress hormone cortisol which interacts with glucocorticoid receptors in the hippocampus to improve memory 

    -Elevates the prosocial neuropeptide oxytocin which decreases activation of the amygdala and enhances connection with the therapist

    -Increased levels of dopamine which can destabilize the old memories and help with reconsolidation of new ones 

    -Increased serotonin levels resulting in prosocial and positive affective states. 

    The goal of PTSD treatment is to prevent the patient from being held hostage by these memories. We want to destabilize the old memories, modify them, and reconsolidate the new memories. The trauma still occurred, but the patient no longer has the same fear reaction to the traumatic memories. 

    MDMA-Assisted Therapy proved to be highly effective in individuals with severe PTSD. 

    -In this study investigators gave patients with PTSD 120-180 mg of MDMA along with a trauma focused psychotherapy. There were significant rates of both response and remission compared to placebo. 

    -MDMA was well tolerated 

    -It was granted breakthrough status by the FDA 

    -This was a big deal in the news and media outlets 

    -It needs to be replicated to confirm the results 

    Potential Adverse Effects of MDMA 

    -Potential for abuse and diversion (probably no take homes) 

    -Possible hyperthermia or hyponatremia (more common in the recreational use environment than clinical) 

    -People often engage in prolonged physical activity in hot environments and do not consume enough water this results in dehydration and possible hyperthermia (think large dance party)

    -In the opposite case the person overcompensates and overconsumes water diluting their blood and causing hyponatremia. Excess of anything can cause problems and water is no exception. 

    Blue Monday and Black Tuesday 

    -Use of MDMA can cause low mood, irritability, and fatigue. It can occur for days after recreational use. 

    -In the clinical setting, fatigue, anxiety, low mood, headaches, and nausea can occur in the week after treatment